[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565366":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":38,"locations":25,"responsibleParty":43,"collaborators":46,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":25},{"fullName":5,"class":6},"University of British Columbia","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"5MTHF","EXPERIMENTAL",[12],"Dietary Supplement: 5-MTHF (5-methyltetrahydrofolate)",{"label":14,"type":15,"description":16,"interventionNames":17},"Synthetic folic acid","ACTIVE_COMPARATOR","Folic acid",[18],"Dietary Supplement: Folic Acid",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Folic Acid","folic acid (0.6 mg)",[14],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"5-MTHF (5-methyltetrahydrofolate)","0.625 mg\u002Fd (6S)-5-MTHF",[9],[31,35],{"name":32,"affiliation":33,"role":34},"Crystal D Karakochuk, PhD","The University of British Columbia","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Kelsey M Cochrane, PhD","University of Saskatchewan",[39],{"name":32,"role":40,"phone":41,"phoneExt":25,"email":42},"CONTACT","604-822-0421","crystal.karakochuk@ubc.ca",{"type":34,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Crystal Karakochuk","Associate Professor, Human Nutrition",[47],{"name":37,"class":6},"100565366","preconception-folic-acid-clinical-efficacy-preface-trial-100565366",false,"NCT06641245","PREconception Folic Acid Clinical Efficacy (PREFACE) Trial","PREFACE","Inclusion Criteria:\n\n* Non-pregnant females who are:\n* Currently trying to become pregnant;\n* Aged 19-42 years;\n* Low risk for an NTD-affected pregnancy\n\nExclusion Criteria:\n\n* Trying to conceive for ≥6 months (as \\~90% of pregnancies occur after 6 months of trying);\n* Diagnosed ovulatory disorders (polycystic ovary syndrome, endometriosis, or menstrual irregularity);\n* More than 2 miscarriages in the past year;\n* Undergoing fertility assistance (including current IVF or intrauterine insemination);\n* Pre-existing medical condition known to impact maternal folate status (malabsorptive and inflammatory bowel diseases, active celiac disease, gastric bypass surgery, type 1 or 2 diabetes mellitus);\n* Lifestyle factors known to impact maternal folate status (current smoking, \\>6 alcoholic drinks per week, recreational drug use);\n* On the female or male side of those trying to conceive: personal NTD history, previous NTD-affected pregnancy, or personal or family history of other folate sensitive congenital anomalies;\n* Use of folate-inhibiting medications (Chloramphenicol, Methotrexate, Metformin, Sulfasalazine, Phenobarbital, Phenytoin, Primidone, Triamterene, Barbiturates).","FEMALE","19 Years","42 Years",{"count":59,"type":60},272,"ESTIMATED","INTERVENTIONAL",[63],"NA","A study to help understand what forms of folic acid are most effective to increase folate status during pregnancy for the best protection against neural tube defects",[66,67,68,69],"Folate","Folate Bioavailability","Clinical Trials","Pregnancy",[16,66,71,72,73,74],"Methylfolate","5-MTHF","RBC Folate","Placental Growth Factor","NOT_YET_RECRUITING","2024-10-17",{"date":78,"type":79},"2024-10-21","ACTUAL",{"date":81,"type":60},"2025-01-31",{"date":83,"type":60},"2030-01-31",{"name":5,"class":6}]